{
    "doi": "https://doi.org/10.1182/blood.V104.11.891.891",
    "article_title": "Rituximab-Supplemented High-Dose Sequential (HDS) Chemotherapy with Autograft Is Highly Effective in High-Risk (aaIPI 2\u20133) Diffuse Large B-Cell Lymphoma: Results of a Prospective Multicenter Study on 91 Consecutive Patients Treated at Diagnosis. ",
    "article_date": "November 16, 2004",
    "session_type": "Poster Sessions",
    "abstract_text": "Recent trials have shown that anti-CD20 monoclonal antibody Rituximab may be effectively employed in association with high-dose (hd) chemotherapy and peripheral blood progenitor cell (PBPC) autograft in the management of high-risk B-cell lymphoma. Addition of Rituximab has a dual effect: increased tumour cytoreduction and in vivo purging prior to PBPC harvesting. We here report the results of a prospective, multicenter trial evaluating Rituximab-supplemented hd-sequential chemotherapy (R-HDS) as frontline treatment in patients with high-risk Diffuse Large B-Cell Lymphoma (DLBCL). So far, 6 Italian Centres associated to GITIL have participated to the study. Eligibility criteria included: i. biopsy-proven DLBCL, with CD20+ phenotype; ii. no previous cytotoxic treatments; iii. age between 16\u201360 yrs.; iv. advanced stage disease with 2\u20133 aaIPI score. The R-HDS regimen includes an initial debulkying (3 APO courses) and then the sequential administration, at 15\u201320 day intervals, of: i. cyclophosphamide (CY) 7gr/sqm (day 1) + Rituximab 375mg/sqm (day +2 and +10), followed by PBPC harvest; ii. Ara-C 2gr/sqm b.i.d. for 6 days, reinfusion of 1\u20133x106 autologous CD34+ve cells/kg (day 7) and then Rituximab 375mg/sqm (day +8 and day +18); iii. etoposide 2.4gr/sqm day +1 + Cisplatin 100mg/sqm day +2; iv. a final myeloablative regimen (Mitoxantrone 60mg/sqm + L-Pam 180mg/sqm), with PBPC autograft (\u22655x10 6 CD34+ve cells/kg) + Rituximab 375 mg/sqm (day +30 and +37); v. involved-field radiotherapy on areas of previous bulky lesions or residual lesions, within 2\u20133 mos. following autograft. Presently, 91 patients (median age: 48 yrs.) have been enrolled and are evaluable. They all had 2 (58) or 3 (33) aaIPI score; in addition, 63 (69%) presented with disease-related symptoms, 52 (57%) had extranodal disease, and 27 (30%) had BM involvement. There were 4 early toxic deaths (three due to sepsis following CY, Ara-C and autograft, respectively, and one due to leucoencephalopathy from JC-virus infection 2 mos. after autograft); one more toxic death due to pneumonia occurred at 10 mos. after R-HDS, for an overall TRM of 5.5%. In addition, 21 patients had CMV or VZV reactivation that resolved after antiviral therapy. Overall 73 patients (80 %) reached CR. So far, at a median follow-up of 24 mos., 76 patients (83.5%) are alive and 68 (75%) are in continuous CR (CCR), with 4.3-yr OS and and EFS projections of 80% and 74%, respectively. There was a trend towards a better outcome in aaIPI 2 vs. 3, although the difference was not statistically significative. Among 27 patients with BM+, 17 (63%) are presently in CCR, at a median follow-up of 25 mos. In conclusion, R-HDS was feasible at the multicenter level although the occurrence of severe infectious complications should not be underestimated. Nevertheless, both CR rate and survival curve projections compare favorably with the poor outcome usually observed in aaIPI 2\u20133 patients managed with conventional chemotherapy. The results here presented urge a comparative analysis between conventional vs. intensified Rituximab-supplemented chemoimmunotherapy in younger patients with high-risk DLBCL.",
    "topics": [
        "chemotherapy regimen",
        "diffuse large b-cell lymphoma",
        "rituximab",
        "transplantation, autologous",
        "cytarabine",
        "follow-up",
        "antiviral agents",
        "biopsy",
        "cisplatin",
        "cyclophosphamide"
    ],
    "author_names": [
        "Manuela Zanni, MD",
        "Massimo Di Nicola, MD",
        "Caterina Patti, MD",
        "Claudia Castellino, MD",
        "Alessandra Pescarollo, MD",
        "Valerio Zoli, MD",
        "Daniele Caracciolo, MD",
        "Michele Magni, MD",
        "Liliana Devizzi, MD",
        "Mario Boccadoro, MD",
        "Ignazio Majolino, MD",
        "Marco Bregni, MD",
        "Andrea Gallamini, MD",
        "Salvo Mirto, MD",
        "Marco Ladetto, MD",
        "Alessandro M. Gianni, MD",
        "Corrado Tarella, MD"
    ],
    "author_dict_list": [
        {
            "author_name": "Manuela Zanni, MD",
            "author_affiliations": [
                "on behalf of, Gruppo Italiano Terapie Innovative nei Linfomi (GITIL), Italy"
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Massimo Di Nicola, MD",
            "author_affiliations": [
                "on behalf of, Gruppo Italiano Terapie Innovative nei Linfomi (GITIL), Italy"
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Caterina Patti, MD",
            "author_affiliations": [
                "on behalf of, Gruppo Italiano Terapie Innovative nei Linfomi (GITIL), Italy"
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Claudia Castellino, MD",
            "author_affiliations": [
                "on behalf of, Gruppo Italiano Terapie Innovative nei Linfomi (GITIL), Italy"
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Alessandra Pescarollo, MD",
            "author_affiliations": [
                "on behalf of, Gruppo Italiano Terapie Innovative nei Linfomi (GITIL), Italy"
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Valerio Zoli, MD",
            "author_affiliations": [
                "on behalf of, Gruppo Italiano Terapie Innovative nei Linfomi (GITIL), Italy"
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Daniele Caracciolo, MD",
            "author_affiliations": [
                "on behalf of, Gruppo Italiano Terapie Innovative nei Linfomi (GITIL), Italy"
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Michele Magni, MD",
            "author_affiliations": [
                "on behalf of, Gruppo Italiano Terapie Innovative nei Linfomi (GITIL), Italy"
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Liliana Devizzi, MD",
            "author_affiliations": [
                "on behalf of, Gruppo Italiano Terapie Innovative nei Linfomi (GITIL), Italy"
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Mario Boccadoro, MD",
            "author_affiliations": [
                "on behalf of, Gruppo Italiano Terapie Innovative nei Linfomi (GITIL), Italy"
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Ignazio Majolino, MD",
            "author_affiliations": [
                "on behalf of, Gruppo Italiano Terapie Innovative nei Linfomi (GITIL), Italy"
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Marco Bregni, MD",
            "author_affiliations": [
                "on behalf of, Gruppo Italiano Terapie Innovative nei Linfomi (GITIL), Italy"
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Andrea Gallamini, MD",
            "author_affiliations": [
                "on behalf of, Gruppo Italiano Terapie Innovative nei Linfomi (GITIL), Italy"
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Salvo Mirto, MD",
            "author_affiliations": [
                "on behalf of, Gruppo Italiano Terapie Innovative nei Linfomi (GITIL), Italy"
            ],
            "author_rank": 14,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Marco Ladetto, MD",
            "author_affiliations": [
                "on behalf of, Gruppo Italiano Terapie Innovative nei Linfomi (GITIL), Italy"
            ],
            "author_rank": 15,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Alessandro M. Gianni, MD",
            "author_affiliations": [
                "on behalf of, Gruppo Italiano Terapie Innovative nei Linfomi (GITIL), Italy"
            ],
            "author_rank": 16,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Corrado Tarella, MD",
            "author_affiliations": [
                "on behalf of, Gruppo Italiano Terapie Innovative nei Linfomi (GITIL), Italy"
            ],
            "author_rank": 17,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-04-24T12:56:00",
    "is_scraped": "1"
}